What are the efficacy, functions and side effects of Tobramycin Inhalation Solution?

Tobramycin inhalation solution is suitable for the treatment of patients with Pseudomonas aeruginosa cystic fibrosis. By changing the route of administration from intravenous injection to local inhalation, it can increase the local drug concentration in the lungs while avoiding systemic toxicity and significantly reducing the risk of drug resistance. It is suitable for long-term maintenance treatment. The efficacy and safety of tobramycin inhalation solution in adult patients have been confirmed in clinical trials.

Tobramycin Inhalation Solution Efficacy

An aminoglycoside antibacterial drug that works by disrupting protein synthesis in bacterial cells, ultimately leading to cell death. Tobramycin has antibacterial activity against a variety of Gram-negative bacteria, including Pseudomonas aeruginosa.

Tobramycin inhalation solution

In a double-blind, single-cycle study, 59 patients were randomly assigned to receive tobramycin inhalation solution (n=29) or placebo (n=30) for one cycle of 28 days on and 28 days off, as measured by the absolute change in FEV 1% predicted from baseline to the end of cycle 1 in the primary analysis population.

Tobramycin inhalation solution significantly improved patients' lung function compared with placebo, resulting in an absolute increase in FEV of 1% predicted of 16% with tobramycin inhalation solution and only 5% with placebo.

In another study, the efficacy and safety of piperacillin/tazobactam intravenous infusion combined with aerosolized tobramycin in the treatment of pulmonary Pseudomonas aeruginosa infection was studied, and 94 patients with pulmonary Pseudomonas aeruginosa infection were included.

They were randomly divided into an observation group of 47 cases and a control group of 45 cases. The control group was given intravenous infusion of piperacillin/tazobactam and tobramycin, while the observation group was given intravenous infusion of piperacillin/tazobactam and tobramycin aerosol inhalation treatment. The efficacy and adverse reactions of the two groups were compared.

Results After 2 weeks of treatment, the clinical pulmonary infection score, sputum culture Pseudomonas aeruginosa negative conversion time and hospitalization time in the observation group were lower than those in the control group (t=6.753, 7.321, 11.362, all P<0.05). The total effective rate of the observation group was 91.5%, which was significantly higher than the 77.8% of the control group.

Tobramycin Inhalation Solution Side Effects

The main symptoms of tobramycin inhalation solution include decreased forced expiratory volume, rales, increased erythrocyte sedimentation rate, dysphonia, voice changes, wheezing, epistaxis, sore throat, bronchitis, tonsillitis, diarrhea, decreased appetite, eosinophilia, increased immunoglobulin, hearing loss, tinnitus, etc.

Treatment measures for side effects of tobramycin inhalation solution

1. Voice changes: Usually they will disappear on their own after stopping the drug, but if severe dysphonia or hoarseness occurs, you should stop using the drug immediately and consult a doctor for diagnosis and treatment as soon as possible.

2. Hearing loss or tinnitus: These are serious side effects. You should stop using tobramycin inhalation solution immediately and consult a doctor for diagnosis and treatment as soon as possible.

3. Decreased appetite: Maintain a regular eating schedule to avoid hunger and overeating, and moderate exercise can help increase appetite and promote body metabolism. You can add an appropriate amount of spices when eating, such as coriander, lemon juice, etc. to increase appetite.

When using tobramycin inhalation solution, you should strictly follow the doctor's advice and medication regimen, and pay close attention to your physical condition. If the side effects are severe or persistent, you should stop using the drug immediately and consult a doctor for diagnosis and treatment as soon as possible.

References:

Deng Zhiping, Zhou Ling, Yang Ying, et al. Piperacillin/tazobactam intravenous infusion combined with tobramycin aerosol inhalation in the treatment of pulmonary Pseudomonas aeruginosa infection. China Primary Medicine, 2014, 21(10):1510-1512.DOI:10.3760/cma.j.issn.1008-6706.2014.10.031

Recommended related articles: